Results 21 to 30 of about 37,271 (160)

Učinkovitost in najpogostejši neželeni učinki zdravljenja z zaviralci od ciklina odvisnih kinaz 4 in 6 (CDK 4/6) pri metastatskem raku dojke

open access: yesOnkologija, 2021
Zaviralci od ciklina odvisnih kinaz (CDK)4/6 so relativno nova tarčna zdravila pri raku dojk, ki jih uporabljamo pri hormonsko odvisnem HER-2 negativnem podtipu za bolnice z lokalno napredovalim ali razsejanim rakom.
Nina Privšek, Cvetka Grašič Kuhar
doaj   +1 more source

Stališča onkologov o bolniški odsotnosti bolnic z rakom dojk, ki so v delovnem razmerju

open access: yesOnkologija, 2022
Izhodišča: Optimizacija rehabilitacije onkoloških bolnikov in njihova vrnitev na delo je pomembna tako za izboljšanje počutja te ranljive skupine kot tudi za zmanjšanje družbenih in finančnih vplivov na celotno družbo.
Ivica Ratoša, Cvetka Grašič Kuhar
doaj   +1 more source

DESAIN RAK DISPLAY UNTUK PENERBIT ZIFATAMA

open access: yesJurnal Kreatif Desain Produk Industri dan Arsitektur, 2021
The low interest of people in reading has closed several book publishers as their books were not in demand. Furthermore, there are some publishers who sell their books only for private users such as Zifatama book publisher in Sidoarjo.
Omar Mukhtar, Faza Wahmuda
semanticscholar   +1 more source

Pengenalan Konsep Perkalian Menggunakan Media Rak Telur Rainbow pada Anak Usia Dini

open access: yes, 2020
Matematika selama ini dianggap materi pembelajaran paling menyeramkan, sehingga banyak anak-anak kurang tertarik untuk mempelajarinya, salah satunya yaitu materi tentang perkalian.Oleh sebab itu pada pembelajaran di SD kelas rendah guru harus memberikan ...
Ihsan Maulana   +2 more
semanticscholar   +1 more source

Samoocena znanja študentk zdravstvene nege o raku dojk

open access: yesRevija za Zdravstvene Vede, 2022
Rak dojke je najpogosteje pojavljajoča se oblika raka pri ženskah. Cilj raziskave je bil ugotoviti samooceno znanja študentk zdravstvene nege o raku dojk, samopregledovanju ter njegovem načinu in pogostosti izvajanja.
Neža Lesjak, Suzana Mlinar
doaj  

Rak dojke i očuvanje plodnosti

open access: yesBolesti dojke, 2023
Predmeopauzalne žene čine ko 15-25% svih bolesnica sa rakom dojke, a 7-8% bolesnica mlađe je od 40 godina, iako u zadnje vrijeme pratimo porast pojavnosti raka u mlađoj populaciji. S obzirom na to da je liječenje ranog raka dojke sve uspješnije te da se znatno podigao prosjek dobi prve trudnoće, sve važnije postaje pitanje očuvanja plodnosti kod žena ...
Marijana Jazvić   +4 more
openaire   +1 more source

TREATMENT POSSIBILITIES OF MENOPAUSAL SYMPTOMS IN BREAST CANCER PATIENTS

open access: yesZdravniški Vestnik, 2018
Background. Breast cancer is the most common cancer in women. Menopausal symptoms, which can highly reduce quality of life in women of all ages, are frequent side-effects of systemic treatment of early breast cancer whether treated by hormonal or ...
Darja Arko
doaj   +1 more source

Malignant melanoma : awareness of malignant melanoma, risk factors and related behavior towards them among adolescents in Slovenia [PDF]

open access: yes, 2018
Incidenca malignega melanoma v Sloveniji v zadnjih desetletjih strmo narašča, poznavanje malignega melanoma in dejavnikov tveganja pa je med populacijo še vedno vprašljivo in malo raziskano.
Leskovšek, Katja, Ocvirk, Janja
core   +2 more sources

DIAGNOSTIC METHODS IN BREAST CANCER DETECTION

open access: yesZdravniški Vestnik, 2018
Background. In the world as well as in Slovenia, breast cancer is the most frequent female cancer. Due to its high incidence, it appears to be a serious health and economic problem. Content.
Kristijana Hertl
doaj   +1 more source

Successful treatment with pazopanib plus PD-1 inhibitor and RAK cells for advanced primary hepatic angiosarcoma: a case report

open access: yesBMC Cancer, 2018
Primary hepatic angiosarcoma (PHA) is a rare and aggressive solid tumor, with high rates of local recurrence and distant metastasis, and poor prognosis. There are no established treatment guidelines for PHA.
Yu Qiao   +14 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy